Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma

Inclusion Criteria: * Written informed consent (signed and dated). * Age equal or greater than 18 at the time of consent. * Histologically confirmed follicular NHL according to the Revised European American Lymphoma (REAL)/ World Health Organization (WHO) classification (from initial diagnosis) Grades 1,2, or 3a. * At least 2 malignant lymph nodes of similar size (\>1 cm in minimal dimension) and location that are readily accessible for excisional biopsy at the time of study entry. * Consent to 1 pretreatment and 1 post-treatment excisional biopsy of accessible tumor. * Acceptable hematologic, hepatic, and renal function parameters. * WHO Performance Status equal or less than 2. * Subjects of reproductive potential must agree to follow accepted birth control methods. Exclusion Criteria: * Presence of lymphoma in CNS. * Previous systemic anticancer treatment for NHL (including but not limited to radiation, myeloablative, or investigational therapy). * Concurrent treatment with systemic steroids within 14 days of Day 1. * Evidence of transformed lymphoma. * Presence of malignancies within 3 years of Study Day 1 (except for adequately treated carcinoma in situ of the cervix, ductal carcinoma in situ (DCIS) of breast, or basal or squamous cell skin cancer). * History of HIV infection or AIDS. * Serious nonmalignant disease. * Pregnant. * Inability to comply with study and follow-up procedures. * Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug.